Page 2,069«..1020..2,0682,0692,0702,071..2,0802,090..»

Stem Cell Research & Therapy | Full text …

Posted: July 20, 2014 at 6:40 am

Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C: Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases.

Nat Rev Rheumatol 2009, 5:392-399. PubMedAbstract | PublisherFullText

da Silva Meirelles L, Chagastelles PC, Nardi NB: Mesenchymal stem cells reside in virtually all post-natal organs and tissues.

J Cell Sci 2006, 119:2204-2213. PubMedAbstract | PublisherFullText

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells.

Science 1999, 284:143-147. PubMedAbstract | PublisherFullText

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Cytotherapy 2006, 8:315-317. PubMedAbstract | PublisherFullText

Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F: Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells.

Stem Cells 2006, 24:386-398. PubMedAbstract | PublisherFullText

See the original post here:
Stem Cell Research & Therapy | Full text ...

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stem Cell Research & Therapy | Full text …

ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy …

Posted: July 20, 2014 at 6:40 am

Published 18 July 2014

ViaCyte a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.

The trial would evaluate the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical Device Master File (called MAF) to the FDA in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate.

"The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials," said Paul Laikind, Ph.D., President and Chief Executive Officer of ViaCyte. "The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organization focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organization for patients with type 1 diabetes," added Dr. Laikind.

ViaCyte's VC-01 product candidate consists of pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line. These cells are then encapsulated by use of ViaCyte's Encaptra device. When implanted under the skin, the PEC-01 cells are designed to mature and further differentiate into insulin-producing beta and other endocrine cells that regulate blood glucose in a manner similar or identical to the normal islets that comprise the endocrine pancreas.

Based on a pre-IND meeting with the FDA and subsequent consultations, ViaCyte is proposing to initiate clinical evaluation of the VC-01 product candidate directly in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. In addition to evaluating the safety of the product candidate in these patients, the study is designed to demonstrate the effectiveness of the VC-01 product candidate in replacing lost endocrine function that is central to the disease.

In the proposed clinical trial, insulin production from the VC-01 implant would be assessed by measuring C-peptide, a biomarker for insulin produced by beta cells that is expected to provide a sensitive measure of efficacy in these patients. As proposed, the trial would also evaluate secondary end-points related to the need for administration of pharmaceutical insulin to control the disease and the incidence of hypoglycemia, a common side effect associated with pharmaceutical insulin usage.

ViaCyte's proprietary Encaptra device is designed to contain the implanted cells, preventing biodistribution, as well as shielding them from the immune system. Although PEC-01 cells are human cells, they are not the patient's actual cells. As such, they are considered an allogeneic graft, which typically requires immunosuppression in order for the recipient to tolerate the implant. However, the Encaptra device is designed to prevent the patient's immune system from accessing the implanted cells, thereby facilitating successful engraftment and subsequent maturation to islets.

The VC-01 product candidate is designed to be placed under the skin of the patient and can be monitored and readily removed, if or when required. The option to remove the cells is designed to provide an important safety benefit for this novel stem cell-derived cell therapy candidate. It is being regulated as a biologic through interaction with the Office of Cell, Tissue and Gene Therapy within CBER at the FDA. Given the combination product nature of the product candidate, the Center for Devices and Radiological Health at the FDA is also involved in its regulation.

View original post here:
ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy ...

Posted in Cell Therapy | Comments Off on ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy …

Lessons Learned from Clinical Trials with Stem Cells – Video

Posted: July 19, 2014 at 5:45 pm


Lessons Learned from Clinical Trials with Stem Cells
Roberto Bolli, MD, FAHA, reviews some of the latest advances and lessons learned from clinical trials with stem cells which he discussed at greater length in a presentation for BCVS 2014 in Las Vegas.

By: AHAScienceNews

Read the original here:
Lessons Learned from Clinical Trials with Stem Cells - Video

Posted in Stem Cell Videos | Comments Off on Lessons Learned from Clinical Trials with Stem Cells – Video

International Stem Cell Corporation Should Win EU Patent Case

Posted: July 18, 2014 at 10:48 pm

The European Union Court of Justice will likely agree that stem cells can be patented, setting a new precedent for scientists to use this controversial method for research and development.

This is an extremely important case with industry-wide consequences, Dr. Simon Craw, of the International Stem Cell Corporation, the American biotech company at the center of the case.

The California-based firm applied for two patents on the technology it uses to produce stem cells but was rejected. European Union laws dictate that embryos cannot be patented on ethical grounds, because they can develop into humans.

Technically, embryos are eggs that have been fertilized with human sperm. But ISC Corp. uses chemicals to activate the cells instead, which are then called parthenotes.

EU Advocate General Pedro Cruz Villaln wrote in a Thursday opinion that since these cells cannot possibly develop into humans, they arent subject to the ethical laws that apply to human beings.

Its a great day for scientific rationale with the Judge correctly recognizing the difference between human parthenogenesis and fertilization, Craw said.

Three years ago, the EU court ruled against patents on discoveries that involve the stem cells, saying the use of human cells in this was immoral.

But it all started in 2004 when Greenpeace challenged a patent filed by a German stem cell researcher, which described a method to turn stem cells into nerve cells.

Greenpeace said the work was contrary to public order because the embryos were destroyed, according to a report in the Guardian from the time.

A group of 13 scientists wrote in the journal Nature that year to express profound concern over the recommended ban, which represents a blow to years of effort to derive medical applications from embryonic stem cells.

Follow this link:
International Stem Cell Corporation Should Win EU Patent Case

Posted in Stem Cells | Comments Off on International Stem Cell Corporation Should Win EU Patent Case

Discovery may make it easier to develop life-saving stem cells

Posted: July 18, 2014 at 10:48 pm

PUBLIC RELEASE DATE:

17-Jul-2014

Contact: Tom Oswald tom.oswald@cabs.msu.edu 517-432-0920 Michigan State University

Not unlike looking for the proverbial needle in a haystack, a team of Michigan State University researchers have found a gene that could be key to the development of stem cells cells that can potentially save millions of lives by morphing into practically any cell in the body.

The gene, known as ASF1A, was not discovered by the team. However, it is at least one of the genes responsible for the mechanism of cellular reprogramming, a phenomenon that can turn one cell type into another, which is key to the making of stem cells.

In a paper published in the journal Science, the researchers describe how they analyzed more than 5,000 genes from a human egg, or oocyte, before determining that the ASF1A, along with another gene known as OCT4 and a helper soluble molecule, were the ones responsible for the reprogramming.

"This has the potential to be a major breakthrough in the way we look at how stem cells are developed," said Elena Gonzalez-Munoz, a former MSU post-doctoral researcher and first author of the paper. "Researchers are just now figuring out how adult somatic cells such as skin cells can be turned into embryonic stem cells. Hopefully this will be the way to understand more about how that mechanism works."

In 2006, an MSU team identified the thousands of genes that reside in the oocyte. It was from those, they concluded, that they could identify the genes responsible for cellular reprogramming.

In 2007, a team of Japanese researchers found that by introducing four other genes into cells, stem cells could be created without the use of a human egg. These cells are called induced pluripotent stem cells, or iPSCs.

"This is important because the iPSCs are derived directly from adult tissue and can be a perfect genetic match for a patient," said Jose Cibelli, an MSU professor of animal science and a member of the team.

Link:
Discovery may make it easier to develop life-saving stem cells

Posted in Stem Cells | Comments Off on Discovery may make it easier to develop life-saving stem cells

Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for …

Posted: July 18, 2014 at 10:48 pm

(PRWEB) July 17, 2014

BCC Research (http://www.bccresearch.com) reveals in its new report, INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS, the global market for induced pluripotent stem cells (iPSCs) is expected to grow to $2.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 19.7%. The Asia-Pacific market, the fastest performing regional segment, is projected to move at a significant CAGR of 22%.

iPSCs are a breakthrough technology recognized by the 2012 Nobel Physiology and Medicine Prize. They are expected to bring revolutionary changes to modern medicine and new hope for reprogramming cells to repair damaged tissues in the human body. They are already useful for drug development and modeling of diseases; scientists hope to use them as powerful tools in tissue transplants since they can be developed from a patient's own cells, avoiding the risk of rejection that is often encountered. The technologies of differentiating iPSCs into various tissue cells are also developing rapidly.

Markets and applications for this technology include academic research, drug development and toxicity testing, regenerative medicine, molecular and cellular engineering, cellular reprogramming, and cell culture.

"The clinical research and service iPSCs market is expected to experience rapid growth in the next few years," says BCC Research biotechnology analyst Mike Fan. "Indeed, iPSCs technology is speeding up and improving the drug discovery process, particularly in promoting personal medicine and the development of personalized drugs and diagnostic tests."

iPSCs are artificially derived from non-pluripotent somatic cells by inducing expression of specific genes. Similar to embryonic stem cells, iPSCs possess pluripotency but reduce associated ethical issues by eliminating the use of embryos. Pluripotency refers to the ability to become any tissue in the body, excluding a placenta.

INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS provides an overview of the global market for iPSCs. It includes analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018, as well as profiles of companies important in the industry.

Editors and reporters, who wish to speak with the analyst, should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.

View original post here:
Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for ...

Posted in Stem Cells | Comments Off on Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for …

'Support' cells in brain play important role in Down syndrome

Posted: July 18, 2014 at 10:46 pm

PUBLIC RELEASE DATE:

18-Jul-2014

Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System

(SACRAMENTO, Calif.) Researchers from UC Davis School of Medicine and Shriners Hospitals for Children Northern California have identified a group of cells in the brain that they say plays an important role in the abnormal neuron development in Down syndrome. After developing a new model for studying the syndrome using patient-derived stem cells, the scientists also found that applying an inexpensive antibiotic to the cells appears to correct many abnormalities in the interaction between the cells and developing neurons.

The findings, which focused on support cells in the brain called astroglial cells, appear online today in Nature Communications.

"We have developed a human cellular model for studying brain development in Down syndrome that allows us to carry out detailed physiological studies and screen possible new therapies," said Wenbin Deng, associate professor of biochemistry and molecular medicine and principal investigator of the study. "This model is more realistic than traditional animal models because it is derived from a patient's own cells."

Down syndrome is the most common chromosomal cause of mild to moderate intellectual disabilities in the United States, where it occurs in one in every 691 live births. It develops when a person has three copies of the 21st chromosome instead of the normal two. While mouse models have traditionally been used in studying the genetic disorder, Deng said the animal model is inadequate because the human brain is more complicated, and much of that complexity arises from astroglia cells, the star-shaped cells that play an important role in the physical structure of the brain as well as in the transmission of nerve impulses.

"Although neurons are regarded as our 'thinking cells,' the astroglia have an extremely important supportive role," said Deng. "Astroglial function is increasingly recognized as a critical factor in neuronal dysfunction in the brain, and this is the first study to show its importance in Down syndrome."

Creating a unique human cellular model

To investigate the role of astroglia in Down syndrome, the research team took skin cells from individuals with Down syndrome and transformed them into stem cells, which are known as induced pluripotent stem cells (iPSC). The cells possess the same genetic make-up as the donor and an ability to grow into different cell types. Deng and his colleagues next induced the stem cells to develop into separate pure populations of astroglial cells and neurons. This allowed them to systematically analyze factors expressed by the astroglia and then study their effects on neuron development.

Read the original:
'Support' cells in brain play important role in Down syndrome

Posted in Genetic medicine | Comments Off on 'Support' cells in brain play important role in Down syndrome

International research team discovers genetic dysfunction connected to hydrocephalus

Posted: July 18, 2014 at 10:46 pm

PUBLIC RELEASE DATE:

17-Jul-2014

Contact: Jeannette Spalding jeannette.spalding@case.edu 216-368-3004 Case Western Reserve University

The mysterious condition once known as "water on the brain" became just a bit less murky this week thanks to a global research group led in part by a Case Western Reserve researcher. Professor Anthony Wynshaw-Boris, MD, PhD, is the co-principal investigator on a study that illustrates how the domino effect of one genetic error can contribute to excessive cerebrospinal fluid surrounding the brains of mice a disorder known as hydrocephalus. The findings appear online July 17 in the journal Neuron.

Cerebrospinal fluid provides a cushion between the organ and the skull, eliminating waste and performing other functions essential to neurological health. Within the brain there are four spaces or ventricles where cerebrospinal fluid flows. Hydrocephalus can be damaging when excessive cerebrospinal fluid widens spaces between ventricles and creates pressure to brain tissue. In humans, hydrocephalus can cause a host of neurological ailments: impairment of balance and coordination, memory loss, headaches and blurred vision, and even damage to the brain.

"Most of the time, hydrocephalus is caused by some sort of physical blockage of the flow of cerebrospinal fluid, so called obstructive hydrocephalus. We demonstrated instead that malfunction of specific genes the Dishevelleds (Dvl genes) triggered hydrocephalus in our mouse models. These genes regulate the precise placement and alignment of cilia within ependymal cells that move cerebrospinal fluid throughout the brain," said Wynshaw-Boris, MD, PhD, James H. Jewell MD '34 Professor of Genetics and Chair, Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine. "This discovery paves the way for more focused research to determine if similar mechanisms can cause hydrocephalus in humans."

Scientists are still at the most nascent stages of understanding different causes and kinds of hydrocephalus. In some instances, the root sources are genetic; in others, the fluid accumulation is attributed to complications of premature birth. This project illuminates one way in which genetic influences contribute to the condition.

Wynshaw-Boris began this collaborative research while a professor in pediatrics at the Institute for Human Genetics and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at the University of California at San Francisco (UCSF) before coming to Case Western Reserve in June 2013. For this hydrocephalus project, he joined fellow principal co-investigator, Arturo Alvarez-Buylla, PhD, professor of neurological surgery, and the Heather and Melanie Muss Endowed Chair, Department of Neurological Surgery, UCSF, in conducting research that proved in mice that Dvl genes regulate the placement and polarity of cilia in ependymal cells that line the ventricles of the brain.

A cilium is a slender protuberance projecting from many cells. In the ependymal cells, multiple cilia protrude from each cell as a bundle or patch, which resembles a horse's tail when beating to move cerebrospinal fluid efficiently. Each cilium must be anchored, sized and shaped correctly, properly placed and aligned in relation to other cilia within the same cell, and the alignment of cilia between cells is also necessary so that the cilia beat with precision to achieve proper movement of fluid in the right direction. It is all about excellent organization: the wrong size, shape or angle of rotation of the bundle of cilia will impede the smooth and appropriate directional flow of the cerebrospinal fluid.

The work in mice by Shinya Ohata, PhD, and Jin Nakatani, PhD, co-first authors who worked in the Alvarez-Buylla and Wynshaw-Boris labs, respectively, and their colleagues demonstrated how normal versus Dvl-deficient mice fared in terms of cilia function. They examined cilia from the ependymal cells of normal mice and found the cilia to be well organized and correctly placed within and between ependymal cells. Investigators even viewed in real time through fluorescent imaging the intricacy with which well-orchestrated cilia swayed to move fluid along in a normal fashion.

View original post here:
International research team discovers genetic dysfunction connected to hydrocephalus

Posted in Genetic medicine | Comments Off on International research team discovers genetic dysfunction connected to hydrocephalus

Scientists use gene therapy to create biological pacemaker

Posted: July 18, 2014 at 10:46 pm

Washington No batteries required: Scientists are creating a biological pacemaker by injecting a gene into the hearts of sick pigs that changed ordinary cardiac cells into a special kind that induces a steady heartbeat.

The study, published Wednesday, is one step toward developing an alternative to electronic pacemakers that are implanted into 300,000 Americans a year.

There are people who desperately need a pacemaker but cant get one safely, said Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, who led the work. This development heralds a new era of gene therapy that one day might offer them an option.

Your heartbeat depends on a natural pacemaker, a small cluster of cells its about the size of a peppercorn, Marban says that generates electrical activity. Called the sinoatrial node, it acts like a metronome to keep the heart pulsing at 60 to 100 beats a minute or so, more when youre active. If that node quits working correctly, hooking the heart to an electronic pacemaker works very well for most people.

But about 2 percent of recipients develop an infection that requires the pacemaker to be removed for weeks until antibiotics wipe out the germs, Marban said. And some fetuses are at risk of stillbirth when their heartbeat falters, a condition called congenital heart block.

For over a decade, teams of researchers have worked to create a biological alternative that might help those kinds of patients, trying such approaches as using stem cells to spur the growth of a new sinoatrial node.

Marbans newest attempt uses gene therapy to reprogram a small number of existing heart muscle cells so that they start looking and acting like natural pacemaker cells instead.

Because pigs hearts are so similar to human hearts, Marbans team studied the approach in 12 laboratory pigs with a defective heart rhythm.

They used a gene named TBX18 that plays a role in the embryonic development of the sinoatrial node. Working through a vein, they injected the gene into some of the pigs hearts in a spot that doesnt normally initiate heartbeats and tracked them for two weeks.

Two days later, treated pigs had faster heartbeats than control pigs who didnt receive the gene, the researchers reported in the journal Science Translational Medicine. That heart rate automatically fluctuated, faster during the day. The treated animals also became more active, without signs of side effects.

Excerpt from:
Scientists use gene therapy to create biological pacemaker

Posted in Gene therapy | Comments Off on Scientists use gene therapy to create biological pacemaker

Scientists using gene therapy to create biological pacemaker

Posted: July 18, 2014 at 10:46 pm

WASHINGTON --

The study, published Wednesday, is one step toward developing an alternative to electronic pacemakers that are implanted into 300,000 Americans a year.

"There are people who desperately need a pacemaker but can't get one safely," said Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, who led the work. "This development heralds a new era of gene therapy" that one day might offer them an option.

Your heartbeat depends on a natural pacemaker, a small cluster of cells - it's about the size of a peppercorn, Marban says - that generates electrical activity. Called the sinoatrial node, it acts like a metronome to keep the heart pulsing at 60 to 100 beats a minute or so, more when you're active. If that node quits working correctly, hooking the heart to an electronic pacemaker works very well for most people.

But about 2 percent of recipients develop an infection that requires the pacemaker to be removed for weeks until antibiotics wipe out the germs, Marban said. And some fetuses are at risk of stillbirth when their heartbeat falters, a condition called congenital heart block.

For over a decade, teams of researchers have worked to create a biological alternative that might help those kinds of patients, trying such approaches as using stem cells to spur the growth of a new sinoatrial node.

Marban's newest attempt uses gene therapy to reprogram a small number of existing heart muscle cells so that they start looking and acting like natural pacemaker cells instead.

Because pigs' hearts are so similar to human hearts, Marban's team studied the approach in 12 laboratory pigs with a defective heart rhythm.

They used a gene named TBX18 that plays a role in the embryonic development of the sinoatrial node. Working through a vein, they injected the gene into some of the pigs' hearts - in a spot that doesn't normally initiate heartbeats - and tracked them for two weeks.

Two days later, treated pigs had faster heartbeats than control pigs who didn't receive the gene, the researchers reported in the journal Science Translational Medicine. That heart rate automatically fluctuated, faster during the day. The treated animals also became more active, without signs of side effects.

More:
Scientists using gene therapy to create biological pacemaker

Posted in Gene therapy | Comments Off on Scientists using gene therapy to create biological pacemaker

Page 2,069«..1020..2,0682,0692,0702,071..2,0802,090..»